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Maternal exposure to microbial pathogens can cause severe 
fetal brain damage that is detectable at birth. The acronym 
TOR CH (toxoplasmosis, other [syphilis, varicella, mumps, 
parvovirus and HIV], rubella, cytomegalovirus, and herpes 
simplex) was first coined to highlight the commonality of the 
observed phenotype secondary to transplacental transmission 
of such microbes (Shin et al., 1976; Fine and Arndt, 1985; 
Donley, 1993). Events involved in the control of infections are 
associated with important immune-mediated collateral dam-
age, with the CNS being more susceptible due to its immune 
privileged status (Konradt and Hunter, 2015). CNS charac-
teristics of  TOR CH include microcephaly, white matter dis-
ease, cerebral atrophy, and calcifications.
Children are considered to have pseudo-TOR CH syn-
drome (PTS) if they display a clinical phenotype indicative of 
in utero exposure to infection, but where the disorder has a 
noninfectious etiology (Reardon et al., 1994; Vivarelli et al., 
2001). The high frequency of consanguinity among families 
with PTS suggests that many cases are genetic, inherited as 
autosomal recessive traits (Vivarelli et al., 2001).
One known rare Mendelian mimic of congenital infec-
tion, overlapping with and falling under the umbrella of PTS, 
is the Aicardi-Goutières syndrome (AGS; OMIM #225750). 
AGS is genetically heterogeneous, caused by mutations in 
any of TREX1, RNA SEH2B, RNA SEH2C, RNA SEH2A, 
SAM HD1, ADAR1, and IFIH1 (Crow and Rehwinkel, 2009; 
Pseudo-TOR CH syndrome (PTS) is characterized by microcephaly, enlarged ventricles, cerebral calcification, and, occasionally, 
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defects resulting in activation of type 1 interferon (IFN) responses have been documented to cause Aicardi-Goutières syn-
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Rice et al., 2012). AGS results from an aberrant accumula-
tion/sensing of IFN-stimulatory nucleic acids, which are 
then misrepresented as viral/non-self by the innate immune 
machinery, leading to the persistent induction of type 1 
IFN-mediated inflammation. Similar increases in type 1 IFN 
production have also been documented in genetic disorders 
in which other components of the IFN signaling pathway 
are constitutively activated (Crow and Casanova, 2014; Liu 
et al., 2014; Crow, 2015; Zhang et al., 2015). The genetic 
cause in most pseudo-TOR CH syndrome patients, however, 
remains largely unknown.
Here, we identify a novel genetic etiology of a type 1 
interferonopathy leading to severe PTS.
RES ULTS AND DIS CUS SION
Clinical characterization
We studied a Turkish consanguineous family (family A) with 
three children (patient 1 [P1], P2, and P3) affected by PTS 
with severe brain damage. We also analyzed a previously re-
ported nonconsanguineous German family (family B) with 
two children (P4 and P5) affected by a similar disorder (Kno-
blauch et al., 2003; Fig.  1  A). Pre- and postnatal brain ul-
trasound and MRI scans showed an enlargement of lateral 
ventricles, calcifications, and hemorrhages (Fig. 1 B). Parents 
in both families are healthy and there was no medical indica-
tion to perform brain MRI scans.
In family A, the antenatal presentation of the condition 
in P1 led to a termination of pregnancy at 23 wk of gestation. 
In P2 and P3, presentation was neonatal and death occurred 
within two weeks. P2 and P3 had severe intracerebral hem-
orrhages and developed liver dysfunction, ascites, and lactic 
acidosis (Fig. 1 B, a–k). P2 also displayed severe thrombocy-
topenia with petechiae. Both siblings developed respiratory 
failure requiring ventilation, together with bradycardia, and 
they died at the ages of 7 and 17 d, respectively (see Supple-
mental Text for clinical details). Blood cells and cerebrospinal 
fluid were not available. In family B, two brothers (P4 and 
P5) presented a PTS-like phenotype with both neurological 
and systemic features, including thrombocytopenia, petechiae, 
ascites, hepatomegaly, and systemic calcifications, and were 
previously reported. (Knoblauch et al., 2003; Fig. 1 B, i). The 
clinical findings for both families are summarized in Table 1.
Identification of loss-of-function USP18 mutations
We performed haplotype linkage analysis assuming the 
autosomal recessive inheritance of a homozygous mutation 
in family A. We demonstrated only one overlapping area of 
homozygosity among affected individuals, on chromosome 
22q11.1-22q11.21, with a suggestive LOD score of 2.83 
(Lander and Kruglyak, 1995) (Fig. 1 C). The linked region 
spans the markers rs5746398-rs5757914 (chr22 :17929926 
-22694656, GRCh37.p10) and contains 200 genes (Fig. 1 C 
and Fig. S1). Whole-exome sequencing failed to identify a 
putative pathogenic mutation, as the area was poorly covered 
(Tables S1 and S2). Capillary DNA sequencing of the missing 
exons in the linked region (Table S3) identified a homozygous 
mutation (c.652C>T) in the three patients that was present 
in the heterozygous state in the healthy brother and both 
parents (primers in Table S4). This variant mapped to exon 7 
of the ubiquitin-specific protease 18 (USP18) gene (OMIM 
#607057) and was predicted to result in replacement of the 
glutamine 218 residue by a premature stop codon (p.Gln218X; 
Fig. 1 D). The variant was not found in 190 Turkish control 
chromosomes, or in the dbSNP or ExAC databases. Analysis 
of 952 DNA samples sequenced by Complete Genomics 
(CG; whole genome sequencing, containing 481 samples of 
Wellderly-aged Americans cohort, 46 public CG data from 
in-house database of the Erasmus Medical Center, and 425 
samples from the 1,000 Genomes Project), which provide 
full coverage of USP18, showed no c.652C>T variant, thus 
indicating that this is an extremely rare variant (Fig. S2).
In family B, Sanger sequencing of USP18 in P4 and 
P5 revealed the same mutation (c.652C>T) present in the 
heterozygous state (Fig. 1 D). Haplotype analysis of 86 SNPs 
on Illumina cyto-snp-850K-B arrays covering the 400-
kb area across the USP18 allele containing the c.652C>T 
change (chr 22: 18483880–18891398, hg19; USP18 spans 
bp 18632666–18660164) revealed a shared c.652C>T al-
lele between the two families, consistent with remote com-
mon ancestry (Table S5). Capillary DNA sequencing of 
USP18 is laborious because of its high homology with 
the pseudogene USP41 (Fig. S3). Genomic sequencing with 
USP18-specific primers did not detect a second mutation in 
family B. Quantitative RT-PCR of USP18 mRNA in fibro-
blasts was performed using primers across exon 4 (forward) to 
exon 6 (reverse), before and after stimulation with IFN-β-1a 
(Fig. 1 E; primer sequences in Table S4). P1 and P2 showed 
low basal and induced transcript levels, whereas P4 and P5 
showed an impaired induced transcript level. On the assump-
tion of a cryptic mutation on the second allele in family B, we 
designed six different primer sets covering the whole cDNA 
(Fig. 2 A), including primers to amplify only the WT allele 
not carrying the c.652C>T mutation (marked with a red x in 
the schematic of Fig. 2 A) and performed RT-PCR.
RT-PCR amplifying exon 1–6 of USP18 yielded the 
expected 782-bp product in the control (C1), the healthy 
heterozygote sibling of family A (Het FamA), and P4 of 
family B, consistent with an intact 5′ portion of the tran-
script. The lower intensity band detected in homozygous P1, 
from family A, was consistent with nonsense-mediated RNA 
decay (Fig. 2 B, product A). RT-PCR amplifying exon 6–9 
of USP18 yielded the expected 393-bp band in C1 and Het 
FamA, but a lower intensity band was detected in the homo-
zygous P1, consistent with nonsense-mediated RNA decay. 
A normal product was detected in P4, consistent with het-
erozygosity at position c.652C>T (Fig. 2 B, product B). RT-
PCR amplifying exon 6–11 of USP18 yielded the expected 
863-bp product in C1 and Het FamA. In P1, this band was 
of lower intensity, consistent with nonsense-mediated decay, 
but importantly, P4 yielded an even more diminished 863-bp 
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Figure 1. Pedigrees, brain imaging, genomic, and expression data. (A) Pedigrees of family A and B (p1, p2, p3, p4, and p5 indicate P1–P5). Family 
A includes three affected siblings (P1, P2, and P3) and one unaffected (heterozygote) sibling; family B includes two affected siblings (P4 and P5). The 
corresponding genotypes are indicated. (B) Prenatal ultrasound (22nd gestational week; a) and fetal MRI (b and c) for P1, showing ventriculomegaly with 
irregular ventricle linings, parenchymal lesions, and cortical destruction. (d–k) Postnatal MRI; d, e, and f (T2-weighted images) and g, h, and i (susceptibil-
ity-weighted images) concern P2, and show extensive parenchymal, basal ganglial, and cerebellar hemorrhages. j (T2 weighted) and k (FLA IR) are images 
of P3, showing bilateral thalamic hemorrhage and white matter hyperintensities. i depicts a postmortem brain analysis for P4, with massive hemorrhagic 
destruction. (C) Haplotype analysis of the linkage area on chromosome 22q in family A, including SNP IDs and location on the chromosome in centimorgans 
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product, consistent with nonsense-mediated decay from one 
allele (c.652T) and a cryptic mutation after exon 9, possibly 
affecting splicing (Fig. 2 B, product C).
RT-PCR amplifying only the WT c.652C allele was 
also performed (red cross in schematic of Fig. 2 A). Ampli-
fying exon 1–7 yielded the expected 830-bp product in C1, 
Het FamA, and P4, consistent with an intact 5′ portion of the 
transcript. The product was essentially absent in the homozy-
gous P1, consistent with primer mismatch (Fig. 2 B, product 
D). Amplifying exon 7–9 yielded the expected 321-bp prod-
uct in P4, similar to C1 and Het FamA, and no product in 
P1, again as a result of primer mismatch (Fig. 2 B, product E).
Amplifying exons 7–11 yielded the expected 791-bp 
product in C1 and Het Fam A, no product in P1, consistent 
with primer mismatch, and no product in P4 consistent with 
a cryptic mutation on the second allele (Fig.  2 B, product 
F). These experiments confirmed the presence of an altered 
transcript in family B.
Additional sequencing of the introns between exon 9 
and 11 did not show any new variant in family B (primers in 
Table S4). This excluded a splicing error as explanation for 
the altered transcript.
Finally, 3′ RACE PCR was performed. For the first 
PCR, 5′ primers starting in exon 6 up to the poly-A tail were 
designed. The resulting product was amplified by nested PCR 
using 5′ primers in exon 7, annealing only to the WT c.652C 
sequence (Fig.  2 A, amplicons G and H). This experiment 
revealed four different products in C1, Het FamA, P1, and P4 
(Fig. 2 C, band 1–4). Upon sequencing, the 1,200-bp product 
(Fig. 2 C, band 1) corresponds to the WT sequence of USP18 
and is present in C1 and Het FamA, but is not detectable in P4. 
A 1,000-bp product (Fig. 2 C, band 2) is only present in P1. 
This product corresponds to an alternative transcript of USP41 
fused with a part of the 3′ distal gene LOC105372866, a result 
of biallelic primer mismatch with the nested primer in USP18. 
An 850-bp product (Fig. 2 C, band 3) is present in C1, Het 
FamA, P1, and P4 and corresponds to an alternative transcript 
of USP41. A product of ∼800 bp is exclusively present in P4 
(Fig. 2 C, band 4). Capillary sequencing of this product shows 
a repeat-rich sequence that maps distal to the 3′ UTR region 
of USP18, suggestive of a large deletion at the 3′ end of USP18 
as the second mutation in family B (cryptic 3′ deletion).
Western blot analysis of lysates prepared from skin fibro-
blasts, with and without IFN-β stimulation, using monoclonal 
antibodies against the N-terminal part of USP18, revealed a 
complete lack of USP18 protein in the patients from both 
family A and B in contrast to healthy controls (Fig.  2  D). 
These results indicate that both the c.652C>T and the cryp-
tic 3′ deletion in USP18 alleles produce no or abnormal 
transcripts, respectively, which are not translated into normal 
USP18 protein. Altogether these genomic, genetic, molecular, 
and biochemical analyses lead us to conclude that the com-
plete USP18 deficiency results from autosomal recessive ho-
mozygous USP18 mutations in family A and from compound 
heterozygous mutations in family B.
USP18 is a type 1 IFN-stimulated gene (ISG) that en-
codes a protein that exerts dual functions: regulatory and en-
zymatic. USP18 is a negative feedback regulator of type I IFN 
signaling (Malakhova et al., 2006). USP18 is also an isopeptidase 
that cleaves the ubiquitin-like ISG15 protein from conjugated 
proteins (Zhang and Zhang, 2011). The study of Usp18−/− mice 
highlighted a role of USP18 in the CNS. Yet, the Usp18−/− phe-
notype appears to be dependent on the genetic background 
of mice. In the fully backcrossed FVB/N background, a ma-
jority of Usp18−/− mice were reported to have a normal life-
span, in the C57BL/6 background Usp18−/− mice died before 
E15.5, and in a mixed C57B/L6 × 129/Sv background they 
reached birth and showed an intermediate phenotype (Zhang 
and Zhang, 2011). All mice displayed varying degrees of neu-
rological signs and brain inflammation, suggesting that the lack 
of USP18 has an impact on the CNS that differs in severity 
depending on the background (Ritchie et al., 2002; Goldmann 
et al., 2015). These CNS alterations were reminiscent of the 
sequelae of viral infection (Ritchie et al., 2002). Importantly, 
none of these diverse murine phenotypes were recognized as 
potential mimics of the human pseudo-TOR CH syndrome.
Patient brain pathology and activation 
of innate immune response
In vivo brain imaging in USP18-deficient patients mostly 
showed severe hemorrhage, with findings reminiscent of 
those in other cases of perinatal hemorrhage, such as genetic 
porencephaly caused by COL4A1 and COL4A2 mutations 
(Meuwissen et al., 2015). Genetic testing in a cohort of 38 pa-
tients with isolated prenatal or infantile cerebral hemorrhage, 
where COL4A1 and COL4A2 mutations had been excluded, 
failed to identify additional USP18 mutations. We therefore 
deduce that USP18 mutations are infrequent.
Postmortem fetal brain pathology in P1 showed mi-
croencephaly, with a brain weight more than three standard 
deviations below the mean value for gestational weight 
(35 g), a thin cortex, and enlarged ventricles. At hematoxy-
(CM). The region between the red lines is homozygous in the three affected individuals and heterozygous in the unaffected sibling. (D) Electropherograms 
of DNA sequencing reactions, showing the USP18 homozygote c.652C>T, p.Q218X mutation in P1, the heterozygous mutation in his father (identical to that 
of the mother and the healthy brother) and in P4 of family B, and the WT sequence of a healthy control (each repeated twice). (E) USP18 expression before 
and after 24-h stimulation with IFN-β-1a in cultured fibroblasts from P1 and P2 (family A), P4 and P5 (family B), and three healthy controls (C1, C2, and C3) 
tested by quantitative RT-PCR using primers amplifying exon 4–6 of USP18 (for primer sequences see Table S4) and normalized against the housekeeping 
gene RNF111. One unstimulated control is set as 1.0 on the y-axis, which allows fold-change comparison. Error bars, SD. RU, relative units. Cumulative data 
of two independent experiments under identical conditions. *, P < 0.05, unpaired Student’s t test for each patient sample versus three controls.
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lin and eosin (H&E) staining, there was irregular ependymal 
layering with curvilinear shape (Fig. 2 E, a), columnar ar-
rangement, and focal erosion (Fig. 2 E, b), compared with 
age-matched control (Fig.  2 E, c). There were trajectories 
of polymicrogyria reflecting defective neuronal migration 
(Fig.  2 E, d). In the white matter, heterotopic neural cell 
clusters were observed. In the layers below the ependyme, 
areas of hemorrhage with hemosiderin-laden macrophages 
were observed (Fig. 2 E, e, f, and g), with lysis, rarefaction, 
necrosis, and dystrophic calcification in the germinal matrix 
areas, the white matter, and the cortex. We next stained the 
brains of the patient and control with markers for vessels 
(CD34), microglia (Iba-1), MHC class II (HLA-DR), and 
astrocytes (GFAP; Fig.  2  F). In the patient brain, there is 
a strong induction of the brain innate immune system, as 
indicated by the robust presence of astrocytes, microglia, and 
up-regulation of MHC class II molecules. Positive staining 
for phosphorylated STAT1 (pSTAT1) in the patient versus 
the control brain (Fig. 2 F, pSTAT1) was suggestive of acti-
vation of type I IFN pathway.
Enhanced induction of ISG transcripts in patient 
fibroblasts after IFN stimulation
USP18 functions as a negative feedback regulator of type 
1 IFN signaling, down-regulating STAT-mediated ISG 
transcription. qRT-PCR was performed on cDNA from 
P1 and P2 and from control fibroblasts, with and without 
IFN-α stimulation, to determine the level of expression of 
several ISGs, IFIT1, MX2, and ISG15. Transcripts for the 
IFIT1, MX2, and ISG15 were much more abundant in the 
cells of P1 and P2 than in those of controls after stimula-
tion with IFN (Fig. 3, A–C). Next, we monitored the levels 
of phosphorylated STAT2 and of the ISG-encoded proteins 
MX1, IFIT1, USP18, and ISG15 in patient and control cells 
Table 1. Clinical data
 Characteristics Family A  Family B (ref. Knoblauch) 
P1 P2 P3 P4 P5
Sex Female Male Male Male Male
Age at 
presentation
Antenatal (22 GW) Day 1 Day 1 Antenatal Antenatal
Born at GW Termination of pregnancy 30 5/7 31 2/7 37 32
Timing of death 23 5/7 GW 1 wk 17 d 22 d 12 d
Head 
circumference
Small, no value 29 cm (+1 SD) 27.5 cm (0 SD) 33 cm (0 SD) 30.5 cm (+1 SD)
Birth weight NA 1,600 g (−0 SD) 1,694 g (−0.5 SD) 2,300 g (−2 SD) 1,830 g (−1 SD)
Respiratory 
distress
NA + (no spontaneous 
respiration)
+ (ventilation within hours) + (ventilation within hours) + (no spontaneous 
respiration)
Seizures NA − (subclinical epileptic 
activity on EEG)
+ + +
Brain MRI Microcephaly BS, BG, CBL, IV, P 
hemorrhage
P, CBL, BG hemorrhage Massive cerebral hemorrhage Periventricular signal 
intensities due to multiple 
small hemorrhages
SC, BG, and PV calcification No clear calcifications No clear calcifications Enlarged lateral ventricles Septum pellucidum cyst, 
Cavum vergae, lack of 
gyration of temporal 
lobes, diminished gyration 
of parietal lobes 
Cortical destruction Normal gyration Cortical necrosis Cerebellar hypoplasia
PV white matter abnormalities Malformations BS and PF
Loss of white/gray matter 
demarcation
Brain CT: calcifications
Thoracic x-ray NP Normal Normal Axillary calcifications, thin 
ribs, metaphyseal bands of 
humerus
Calcifications along M. 
sternocleidomastoideus, 
thin ribs
Abdominal 
ultrasound
NP Normal Ascites, abnormal renal cortex/
parenchyma differentiation
NP Hepatomegaly, pleural 
effusions
Cardiological 
examination
NP PDA ASD type II, PDA, NP NP
Bradycardia Bradycardia,
Widening of right and left 
coronary artery
Eye examination NP Normal Thinning of retinal vessels NP Normal
Blood 
hematology/
NA Thrombocytopenia, SGOT/SGPT/ammonia and 
lactate elevation
Thrombocytopenia, Thrombocytopenia
chemistry SGOT/SGPT/ammonia and 
lactate elevation 
Dyserythropoiesis on bone 
marrow aspiration
ASD, atrium septum defect; BG, basal ganglia; BS, brain stem; CBL, cerebellum; CT, computed tomography; GW, gestational week; IV, intraventricular; P, parenchymal; NA, not available; NP, 
not performed; PDA, persistent ductus arteriosus; PF, posterior fossa; PV, periventricular; SC, subcortical.
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Figure 2. USP18 transcripts, protein, and brain pathology. (A) Schematic of the genomic DNA and mRNA USP18, with coding regions in blue, UTRs in 
green, and the c.652C>T mutation indicated by the red arrow. RT-PCR primer locations and expected product sizes are shown from A to F in the key, and G 
and H refer to 3′ RACE and nested PCR primers, covering exon 1 to the poly-A tail. PCR primers designed to amplify only the c.652C WT allele are indicated 
by a red x. (B) RT-PCR amplicons obtained using the primer sets schematized in A. C1, control; Het-FamA, healthy heterozygote sibling from family A; P1, 
P1 from family A; P4, P4 from family B. Primers used are listed in Table S4. (C) Nested PCR products of the 3′ RACE cDNA amplification (area indicated in 
A, primer sets G and H). The four bands obtained in C1, P1, P4, and Het-FamA samples, indicated by red numbers, were subjected to capillary sequencing: 
band 1 (∼1,200 bp), band 2 (∼1,000 bp), band 3 (∼850 bp), and band 4 (∼800 bp). Both RT-PCR and 3′ RACE experiments were separately repeated three 
times with identical results. (D) Western blot analysis of the endogenous USP18 protein in cultured fibroblasts from controls and from P1, P2, P4, and P5, 
before and after stimulation for 24 h with IFN-β-1a. Levels of the IFN-inducible ISG15 protein and of GAD PH as control were also measured. In control cells, 
IFN-induced USP18 and ISG15 were detected after IFNβ-1a treatment. In patients cells, no USP18 protein was detected. This experiment has been replicated 
twice with separate controls and with identical results. (E) H&E staining of autopsy brain material from P1. Irregular ependyme with a curvilinear shape, 
columnar arrangement (a), and numerous ependymal canals (b) are present, compared with an age-matched control case (c).Trajectories of polymicrogyria 
(d). Vessel-associated dystrophic calcifications in the white matter (e). (f) Magnification of e: with arrows showing hemosiderophages. (g) Prussian blue 
staining for iron. Bars: 50 µm (a and f), 100 µm (e); magnification in b and c is equal to a; magnification in d is equal to e. (F) P1 and age-matched control 
brain material. Immunohistochemistry for vessels (CD34) and for the presence of innate immune response activation in the white matter, using markers 
for the microglial ionized calcium-binding adaptor molecule 1 (Iba-1), MHC class II (HLA-DR), and the astrocyte marker glial fibrillary acidic protein (GFAP). 
pSTAT1 is used as marker for type I IFN response activation (inset showing a magnification of positive cells in the patient). Bars: (CD34 control) 50 µm (mag-
nification in CD34, Iba-1, HLA-DR, and GFAP are equal to CD34 control); (pSTAT1 control) 50 µM (magnification in the patient is the same as in the control).
Transduction of patient fibroblasts with USP18 rescues 
the enhanced induction of ISGs and the increased 
global protein ISGylation
To ascertain that this enhanced type 1 IFN response with 
up-regulation of ISG expression was indeed caused by 
(Fig. 3 D). Persistent STAT2 phosphorylation and high lev-
els of induced MX1 and IFIT1 proteins were detected in 
patients’ cells as compared with WT controls. Analysis of the 
non–type I IFN-related gene product IL-6 showed no abnor-
mal regulation (Fig. 3 E).
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USP18 deficiency, we transduced USP18-deficient fibro-
blasts from P1 and P2 and control fibroblasts with lentivi-
ral particles (LV)-expressing luciferase (Luc) or WT USP18. 
Unlike LV-Luc, LV-WT USP18 completely rescued the 
enhanced induction of ISGs at the mRNA level (Fig.  4, 
A–C). Similarly, at the protein level, unlike LV-Luc, LV-WT 
USP18 transduced patient fibroblasts exhibited reduced lev-
els of phosphorylated STAT2, MX1, and IFIT1 (Fig. 4 D). 
ISGylated proteins are main targets of USP18 protease ac-
tivity (Zhang and Zhang, 2011). We therefore determined 
global ISGylation levels and the amount of unconjugated 
ISG15. Consistently, fibroblasts from P1 and P2 stimulated 
with IFN-α displayed significantly greater amounts of IS-
Gylated proteins than control cells (Fig. 4 E). As expected, 
LV-WT USP18 transduction, but not LV-Luc, decreased 
global protein ISGylation levels (Fig. 4 E). siRNA against 
USP18, but not control siRNA, in primary control fibro-
blasts completely phenocopied USP18-deficient cells when 
challenged with IFN (Fig. 4 F and G). Collectively, these res-
cue experiments indicate that the loss of USP18 is respon-
sible for abnormal activation of IFN signaling. Moreover, 
our results demonstrate that, in humans, USP18-mediated 
regulation of IFN response is crucial for normal CNS de-
velopment, and that its deficiency causes severe PTS. Yet, the 
diversity of phenotypes observed in the Usp18−/− mice of 
different genetic background likely reflects different basal 
levels of IFNs, which itself points to the contribution of 
additional genetic or epigenetic factors.
Figure 3. mRNA and protein expression of USP18 and ISGs, as assessed by qRT-PCR and Western blotting after IFN treatment, and IL-6 
production assessment. (A–C) Primary fibroblasts from C1 and C2 and from P1 and 2 were treated with the indicated doses of IFN-α2b for 12 h, washed 
with PBS, and left to rest for 36 h, after which relative mRNA levels were assessed for the genes indicated, with representative experiment of three with SD 
shown. (D) Primary fibroblasts from two controls (C1 and C2) and P1 and P2 were stimulated with 100 pM IFN-α2 for 8, 20, and 36 h. The levels of phos-
phorylated STAT2 and of the indicated ISG products were analyzed by Western blotting of 20 µg of cell lysate, representative experiment of two shown. RU, 
relative units. IL-6 production at 24 h after stimulation with 10 ng/ml IL-1B or 25 µg/ml Poly(I:C) was measured using ELI SA. Shown are pooled data from 
two independent experiments, each done in duplicates using three different controls and two patient cell lines. Mann-Whitney test was used for statistical 
analyses, with SEM shown (E).
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Figure 4. WT USP18 allele rescues USP18 deficiency. Primary fibroblasts from C1 and C2 and from P1 and P2 were mock-transduced or transduced 
with luciferase-RFP or WT USP18, sorted, and treated with the indicated doses of IFN-α2b for 12 h, washed with PBS, and left to rest for 36 h, after which 
relative mRNA levels were assessed for the genes indicated (A–C) performed three times each with technical triplicates, representative experiment with 
SD shown. The levels of the indicated proteins were compared in fibroblasts from P1 and P2, transduced with USP18 or with the control Luc LV. Cells were 
stimulated and processed as in Fig. 3 D, representative experiment of two shown (D). The levels of free and conjugated ISG15 were analyzed in lysates (40 µg/
lane) from a control (C1), P1 (P1), and USP18-transduced fibroblasts from P1 (P1 LV-USP18), stimulated, and processed as described in Fig. 3 D, representa-
tive experiment of two are shown (E). Primary fibroblasts from C1 were transfected with either control siRNA or siRNA targeting USP18, followed by vehicle 
of IFN stimulation for 36 h, when USP18, GAP DH, free, and conjugated ISG15 were analyzed in lysates, representative of two experiments shown (F), or were 
primed or not for 12 h with 1,000 IU IFN along with P1 USP18−/− cells, followed by 36 h rest when MX1 mRNA levels were assessed, representative of two 
experiments shown, performed in biological duplicates and technical triplicates. Student’s t test was used for statistical analyses with SEM (G). IFNB mRNA 
expression was measured after a 4-h stimulation with 25 µg/ml Poly (I:C), as well as IFN-β production at 24 h, both in control and patient cells. Two control 
and patient cell lines, in triplicates in two independent experiments were used for mRNA measurements; three control and two patient cell lines, in tripli-
cates in three independent experiments were used for IFN-β measurement. Mann-Whitney test was used for statistical analyses with SEM shown (H and I).
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Notably, the brain pathology of USP18-deficient pa-
tients (Fig.  2  E, d) is similar to that observed in cases of 
congenital infection with neurotropic viruses, such as cyto-
megalovirus and lymphocytic choriomeningitis virus, with 
activation of meningeal and hematopoietic-derived macro-
phages and microglia and the induction of cytokines includ-
ing type 1 IFN (Bale, 2009; Bonthius, 2012; Sakao-Suzuki 
et al., 2014). Our observations are consistent with previous 
studies suggesting that, in some congenital viral infections, 
the brain damage may owe as much to the host response as to 
the infectious agent itself (Gresser et al., 1980). This is crucial 
for future considerations on management of congenital infec-
tions, as targeting only the virus itself will not be sufficient to 
avoid permanent damage to the fetus.
Interestingly, the mechanism behind type I interfer-
onopathies described to date in AGS differs from the one 
operating in USP18 deficiency, as type I IFN dysregulation 
in USP18 deficiency is not a result of aberrant induction of 
these cytokines but is caused by an aberrant response to type 
I IFN. In support of this, although body fluids of the patients 
were not stored, IFNB mRNA and protein level were com-
parable to controls when patient cells were stimulated with 
Poly (I:C; Fig. 4, H and I).
Human ISG15 deficiency leads to milder USP18 dys-
function and causes cerebral abnormalities compatible with 
adult life, such as basal ganglia calcification and occasional 
seizures (Zhang et al., 2015). The cells of ISG15-deficient pa-
tients demonstrated reduced, albeit still detectable, amounts 
of USP18, and displayed defective down-regulation of type 
1 IFN signaling. We speculate that biallelic hypomorphic 
USP18 mutations (i.e., leading to residual protein function) 
may cause milder cerebral abnormalities with prolonged sur-
vival, possibly overlapping the phenotypic spectrum of ISG15 
mutations. Therapeutically, USP18 represents an attractive 
target, with agonists being of use in clinical settings where 
there is overabundance of type I IFNs and USP18 antagonists 
acting to prolong the beneficial effects of therapeutic IFNs, as 
in multiple sclerosis, hairy cell leukemia, and melanoma. Like-
wise, in genetic counseling and prenatal diagnosis of severe 
perinatal PTS, USP18 should be added to the list of genes to 
be tested. Collectively, our results establish USP18 deficiency 
as a novel genetic cause of severe PTS.
MAT ERI ALS AND MET HODS
Ethics approval. Written parental consent was obtained. 
Genetic tests were performed according to The Eras-
mus University Medical Center’s local ethics board ap-
proved protocol MEC-2012387.
Linkage analysis. Linkage analysis was performed on Illumina 
CytoSNP12v2.1 array data for the three affected siblings, 
their healthy brother, and both parents of family A. Genotype 
data were available for >300,000 SNPs per individual. Link-
age analysis was performed with Merlin v1.0.1 (in the Easy 
Linkage Plus v5.08 package). An autosomal recessive model 
was specified, with an estimated allele frequency of 0.0001 
and 100% penetrance. Closely spaced SNP markers were used 
for the analysis, so the genome analysis was performed with 
predefined spacings of 0.1 and 0.15 cM. Genomic regions 
with LOD scores >2.5 were considered to be candidate in-
tervals. Haplotypes were constructed and graphic visualiza-
tions were performed with HaploPainter v029.5 (Hoffmann 
and Lindner, 2005) to facilitate inspection and analysis.
Whole-exome sequencing. Whole-exome sequencing was 
performed on DNA extracted from the fibroblasts of P1 and 
peripheral leukocytes from the parents and P2 and P3 of fam-
ily A with the Sure Select All Exome V4 capture kit (Agilent) 
on a HiSeq2000 machine (Illumina). The statistics are pro-
vided in Table S1. BWA version 0.5.9 (Li and Durbin, 2009) 
and NAR WHAL software (Brouwer et al., 2012) were used 
to align reads with the reference genome (hg19). Variants 
were called with GATK (version 1.2–29; McKenna et al., 
2010) and SAMtools (version 0.1.13). Variants were annotated 
with ANN OVAR software (revision 511; Wang et al., 2010) 
and filtered with TIB CO Spotfire version 4.5 (Tables S1 and S2).
Light microscopy and immunohistochemistry. Brain autopsy 
material was fixed in 4% paraformaldehyde and embedded in 
paraffin. Sections (4 µm thick) were cut and stained with 
H&E or Prussian blue, for iron visualization. Immunohisto-
chemical staining was performed with a biotin-avidin and 
alkaline phosphatase/anti-alkaline phosphatase visualization. 
The primary antibodies used were as follows: anti-CD3 
(T cells, rat monoclonal antibody; Serotec), anti-glial fibril-
lary acidic protein (anti-GFAP, rabbit polyclonal antibody; 
Dako), anti–HLA-DR (MHC class II, mouse monoclonal an-
tibody, clone LN3; eBioscience), antiionized calcium-binding 
adaptor molecule (Iba)-1 antibody (microglia, macrophages; 
Wako), anti-CD34 (vessels, clone B-C34; Cell Sciences), and 
anti-pSTAT1 (clone 58D6, #9167; Cell Signaling Technol-
ogy). The pictures were taken with a BZ-9000 Biorevo mi-
croscope (Keyence; Neu-Isenburg)
Sanger sequencing of missing exons in linked area and 
USP18. PCR and Sanger sequencing were conducted accord-
ing to standard methods. The Sanger sequencing of USP18 
was complicated by the presence of a pseudogene with a very 
similar sequence, USP41. Fig. S3 shows the alignment of these 
two genes, highlighting their similarity. Table S3 lists the 
exons for which there was little or no coverage, together with 
the primers used for Sanger sequencing. Table S4 lists the ge-
nomic primers for Sanger sequencing of USP18.
qRT-PCR. qRT-PCR was performed with a KAPA SYBR 
FAST qPCR kit (Kapa Biosystems) in the CFX96 Real-Time 
system (Bio-Rad Laboratories). Thermal cycling conditions 
were as follows: denaturation (95°C for 3 min), followed by 
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35 cycles of denaturation (95°C for 5 min), annealing, and 
extension (60°C for 30 min). Fluorescence detection and data 
analysis were performed with CFX Manager 2.0 (Bio-Rad 
Laboratories). Experiments were performed in triplicate, with 
RNF111 (Entrez Gene ID 54778 [OMIM 605840]) as the 
reference gene for the normalization of expression data (Bus-
tin et al., 2009) and COPS5 (Entrez Gene ID 10987 [OMIM 
604850]) as a secondary housekeeping gene. The primers 
used are also listed in Table S4. For qRT-PCR after transduc-
tion, see Stimulation and qRT-PCR.
Fibroblast culture, cDNA synthesis, and RT-PCR. Fibroblasts 
were routinely tested for mycoplasma infection and were cul-
tured in 75-cm2 culture flasks, in DMEM, to 80% confluence. 
Total RNA was extracted on RNeasy mini columns (QIA 
GEN) according to the manufacturer’s protocol. Reverse 
transcription was performed on 1 µg of RNA in a total vol-
ume of 20 µl, with the iScript cDNA Synthesis kit (Bio-Rad 
Laboratories) used according to the manufacturer’s instruc-
tions (Poulton et al., 2011). RT-PCR was performed using 
FAS TStart Taq DNA polymerase (Sigma-Aldrich) according 
to manufacturer’s instructions. Primers for RT-PCR analysis 
for the experiments shown in Fig. 2 B are listed in Table S4.
3′ RACE PCR. Total RNA from control and patients fibroblasts 
was isolated using TRIzol (Ambion). 3′ RACE PCR was 
performed using the 3′ RACE System for Rapid Amplifica-
tion of cDNA ends (Invitrogen), according to the man-
ufacturer’s instruction.
3′ RACE Universal Amplification Primer (UAP), sup-
plied in the kit, complementary to the adaptor primer, and 
a gene-specific primer designed in exon 6 of USP18 (5′-
CAG AAA CAG CAG CAT GCT CACC-3′) were used for first 
amplification, followed by nested PCR with the UAP and a 
second gene-specific primer designed in exon 7 of USP18 
(5′-CGC CCT GCA CTG CTT CTT CC-3′).
Stimulation of fibroblasts with interferon. Fibroblasts were 
stimulated for 12 or 24  h at 37°C with either 110 U/ml 
human IFN-β-1a (11415–1; pbl interferon source) or 10–
1,000 U/ml IFN-α-2b (Merck IntronA) in complete me-
dium. The IFN was removed by thorough washing with PBS, 
and the cells were either harvested or allowed to rest for 36 h 
at 37°C in normal growth medium. Cells were har-
vested for RNA isolation.
Western blot analysis and siRNA experiments. In Fig. 2 C, 
cell pellets were resuspended in a previously described buffer 
(Francois-Newton et al., 2012; 50  mM Tris/HCl, pH 8.0, 
150 mM NaCl, 1% Triton X100, 0.5% sodium deoxycholate, 
0.03% SDS, and 1 mM Na3VO4). We ran 40 µg of total pro-
tein on a precast Criterion XT 4–12% bis Tris gel (Bio-Rad 
Laboratories). The blots were incubated with anti-USP18 
(1:1,000; rabbit monoclonal; Cell Signaling Technology 
#4813; recognizing residues surrounding amino acid Pro45), 
anti-ISG15 (1:500, rabbit polyclonal), or anti-GAP DH 
(mouse 1:1,000; monoclonal; Li-Cor Biosciences) primary 
antibodies; 680 nm goat anti–rabbit and 800 nm goat anti–
mouse conjugates were used as secondary antibodies. In Figs. 
3 C and 4 (D and E), cell lysates were prepared in modified 
RIPA buffer (50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1% 
NP-40, 0.5% DOC, 0.05% SDS, and 2  mM EDTA) with 
1 mM Na3VO4 and a cocktail of proteases inhibitors (Roche). 
Rec IFN-α2 was provided by D. Gewert (Wellcome Trust, 
London, England). We used antibodies against STAT2 (EMD 
Millipore), phosphorylated Tyr689 STAT2 (EMD Millipore), 
USP18 (Cell Signaling Technology), β-tubulin (Takara Bio 
Inc.), ISG15 (gift from E.C. Borden, Cleveland Clinic, Cleve-
land, OH), IFIT1 (gift from G. Sen, Cleveland Clinic, Cleve-
land, OH), and Mx1 (MxA; gift from O. Haller, University of 
Freiburg, Freiburg, Germany). Signal was detected with en-
hanced chemiluminescence detection reagent (Western 
Lightning; PerkinElmer) and acquired with a Fuji Im-
ageQuant LAS-4000 machine. Control primary human fi-
broblasts were silenced by incubation for 24 h with 25 nM 
USP18-siRNA (Dharmacon; pool-siRNA), followed by 
priming with IFN. siRNA transfections were performed with 
Lipofectamine RNAi max reagent (Invitrogen) according to 
the manufacturer’s instructions.
Transduction. Lentiviral particles were produced by transfect-
ing HEK-293T cells, in the presence of Lipofectamine-2000 
(Invitrogen), with the following constructs: pCAG GS-
VSV-G, pCMV-Gag/Pol, and pTRIP-hUSP18-IRES-RFP 
or pTRIP-luciferase-IRES-RFP. Supernatants were collected 
36  h after transfection and clarified by centrifugation. The 
fibroblasts were covered with lentiviral inoculum and incu-
bated at 37°C. Supplemental growth medium was added, and 
transduction efficiency was checked by fluorescence micros-
copy. Transduced fibroblasts were sorted (FACS Aria II; BD) 
into (−), low (Lo), medium (Med), and high (Hi) expression 
groups on the basis of RFP expression. We focused on the Lo 
expression group. Transduced cell populations were expanded 
and grown in the same conditions as untransduced cells, and 
the level of transduced gene expression was periodically con-
firmed by fluorescence microscopy.
Stimulation and qRT-PCR. Untransduced luciferase- and 
USP18-transduced fibroblasts were treated with 0 U/ml 
(mock), 10 U/ml, 100 U/ml, or 1,000 U/ml interferon α-2b 
(Merck IntronA) in normal growth medium for 12 h at 37°C. 
The IFN was removed by thorough washes with PBS, and the 
cells were allowed to rest for 36 h at 37°C in normal growth 
medium. The cells were then lysed and RNA was extracted 
with a kit, according to the manufacturer’s instructions 
(RNeasy; QIA GEN). RNA was reverse-transcribed accord-
ing to the enzyme manufacturer’s instructions (ABI High Ca-
pacity Reverse transcription). The relative expression levels of 
multiple IFN-stimulated genes (ISGs; MX1, MX2, RSAD2, 
ISG15, IFI44L, and IFIT1) were analyzed by TaqMan quanti-
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tative real-time PCR on technical duplicates (TaqMan 
Universal Master Mix II w/UNG; LightCycler 480 II; 
Roche). The relative expression of the ISGs was calculated by 
the ΔΔCT method, with comparison to the mean value for 
the untreated controls.
Online supplemental material. Fig. S1 shows linkage data and 
haplotyping. Fig. S2 shows CG control alleles. Fig. S3 shows 
alignment of USP18 and USP41. Table S1 shows exome 
sequencing data. Table S2 lists filtering steps for family A. 
Table S3 lists the exons for which there was little or no 
coverage, together with the primers used for Sanger 
sequencing. Table S4 lists the genomic primers for Sanger 
sequencing of USP18. Table S5 lists haplotypes of chromosome 
22q11 in family A and B using Illumina cyto-snp-850 kb 
arrays. Clinical data from family A is provided as supplemental 
text. Online supplemental material is available at http ://www 
.jem .org /cgi /content /full /jem .20151529 /DC1.
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